Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

EMA panel recommends approval of Bluebird Bio’s first gene therapy

A European Medicines Agency panel recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc. as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win the company’s first regulatory nod.

Read More »

Celgene and Acceleron’s Luspatercept Hits Primary Endpoints in Beta-Thalassemia Trial

Celgene Corporation and Acceleron Pharma Inc. indicated the companies’ Phase III clinical trial of luspatercept in beta-thalassemia hit its primary endpoint of erythroid response.

Read More »

Anemia Patients Benefit from bluebird’s LentiGlobin Gene Therapy, Trial Data Shows

Cambridge, Mass.-based bluebird bio’s LentiGlobin gene therapy is increasing hemoglobin levels in anemia patients battling sickle cell disease and beta thalassemia, which reduces the need for blood transfusions in those patients.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom